Canadian Sec - Free Realtime Quote CAD

PharmaTher Holdings Ltd. (PHRM.CN)

0.0500 -0.0050 (-9.09%)

As of 10:03:47 AM EST. Market Open.

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

TMX Newsfile 4d ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

TMX Newsfile 26d ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

TMX Newsfile 2mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Launches New Division to Commercialize Personalized Peptide Products

PREMIUM
MT Newswires 3mo ago

PHRM.CN
-9.09%
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

TMX Newsfile 3mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

TMX Newsfile 5mo ago

PHRM.CN
-9.09%
PHRX.CN

PHRRF
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

TMX Newsfile 5mo ago

PHRM.CN
-9.09%
PHRX.CN

G11.F
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

TMX Newsfile 6mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

TMX Newsfile 6mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

TMX Newsfile 6mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

TMX Newsfile 6mo ago

PHRM.CN
-9.09%
PHRRF
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency

TMX Newsfile 5d ago

PHRRF

PHRM.CN
-9.09%

U.S. markets close in 4h 51m

PharmaTher Holdings Ltd. (PHRM.CN)

PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157

PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies

PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)

PharmaTher Launches New Division to Commercialize Personalized Peptide Products

PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics

PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus

PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness

PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides

PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology

PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency